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Background: This was a prospective observational study conducted over a twelve-month duration in our institute 
to compare the combined effect of metformin and myoinositol with metformin alone. Method: A total of sixty 
patients were included in the study, and they were divided into two groups depending on whether they were 
given the combination or the single drug. Group A (n=30) was given Myoinositol 600 mg+Metformin 500 mg thrice 
a day, and Group B ( n=30) was given only Myoinositol 600 mg thrice a day. The outcome measure was clinical 
pregnancy rate and improvement in clinical and hormonal parameters after drug therapy. Results: BMI (p<0.01), 
modified Ferriman Gallaway score (p>0.05), and the was a significant improvement in the hormonal 
parameters (LH,FSH) in both the groups and the levels were found to be comparable after a period 
of 6 months. The clinical pregnancy rate after six cycles of ovulation was significantly higher in 
Group A as compared to Group B. In Group A, the total clinical pregnancy rate was 43.33%, and in 
Group B, it was 26.67%, respectively, and the end of 6 months and the difference was statistically 
significant (p = <0.01) Conclusion: Equal response in reduction of hormonal levels and clinical and laboratory 
parameters were seen in both groups, while better results in terms of clinical fertility rates were observed in the 
group that was given a combination of myoinositol with metformin.
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IntroductIon
Polycystic ovarian syndrome (PCOS) is the common reason for infertility with anovulatory cycles, and prevalence among 
infertile women is 15-20% [1,2]. This syndrome 
was first described by Stein and Leventhal 
in 1931. It is a disorder characterized by 
excessive secretion of androgens by the ovaries, 
oligomenorrhea, anovulation/oligo- anovulation, 
and insulin resistance and with variable clinical 
manifestations like oligomenorrhoea, hirsutism, 
acne [3]. The pathogenesis of PCOS has not been 
completely elucidated and is multifactorial, with 
the genetic and environmental factors being 
implicated. The resistance to insulin is thought 
to be due to problems in the receptors of insulin 
and post-receptor components of the signaling 
pathway of insulin [4,5].
Hyperinsulinemia due to resistance to insulin 
occurs in roughly 80% of PCOS women with 
central obesity, as well as in 30-40% of thin 
women who have been diagnosed with PCOS [6]. 
Hyperinsulinemia leads to, increase in thecal 
androgen response to LH, increased concentration 
of free androgen, increases circulating level 
of IGF-I, collectively hyperandrogenism [7]. 
Because hyperinsulinemia often plays a role in 
the pathogenesis of PCOS, insulin-sensitizing 
agents have been tried along with oral ovulation 
induction agents in anovulatory infertile PCOS. 
Among insulin sensitizers, metformin and Myo-
inositol have been studied most extensively [8]. 
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Metformin act by decreased hepatic 
gluconeogenesis, increased insulin sensitivity, 
decrease insulin-induced fatty acid oxidation. 
Myo-inositol acts by a membrane-associated 
sodium-dependent inositol co-transporter GLUT4 
as the second messenger of insulin signal and 
decreases hyperinsulinemia improves ovarian 
function decreases LH/FSH ratio, reduces serum 
androgens [9].
As the two insulin sensitizers act through 
different mechanisms, these may be combined 
to act synergistically to improve metabolic and 
reproductive outcomes in infertile PCOS women. 
The present study was planned to study the 
effect of combined Myo-inositol and metformin as 
compared to myo-inositol alone with regards to 
their reproductive outcome and positive changes 
in metabolic and hormonal parameters in PCOS 
women with infertility who are undergoing cycles 
for ovulation induction 
MaterIal and Methodology
Study design: This was a prospective 
observational, comparative clinical study.
Ethics approval: The institutional ethics 
committee approves the study
Study period: Conducted from November 2019 
to November 2020
Locus of study:  Department of Obstetrics and 
Gynaecology, Dr. Vithalrao Vikhe Patil Medical 
College, Ahmadnagar.
Study population: Infertile PCOS women 
(according to Rotterdam criteria) attending 
outpatient departments were screened for the 
study.
Inclusion criteria: Age between 20-36 years who 
failed to conceive for >12mth and bilateral patent 
tubes on hysterosalpingography/laparoscopy.
Exclusion criteria: Thyroid disorder, 
Hyperprolactinemia, Male factor infertility, Type 
1 or Type 2 DM, Pregnancy, Deranged kidney or 
liver function test, Cushing’s disease, Congenital 
Adrenal Hyperplasia, and androgen-secreting 
neoplasms were excluded 
Sample Size: Sample size was calculated by 
open-epi software. The prevalence of PCOS 
women with infertility was found to be 17.6% 
[11].
Sample size n = [DEFF*Np(1-p)]/ [(d2/Z21-
α/2*(N-1)+p*(1-p)]  
{Design effect (for cluster surveys-DEFF):1, 
Confidence limits as % of 100 (absolute ±%) 
(d):10%, Hypothesized % frequency of outcome 
factor in the population (p) 17.6%±10, Population 
size (for finite population correction factor or fpc)
(N): 1000000, CI: 95%, 
Calculated sample size is 56, Final sample size 
= 60}
Grouping: The patients who fell into the 
eligibility criteria were randomly divided into two 
study groups, i.e., Group A (n= 30), that received 
Myoinositol 600mg+ Metformin 500 mg thrice a 
day. Group B (n=30) was given only Myoinositol 
600 mg thrice a day. 
Methodology: Taking detailed history 
pertaining to PCOS and infertility, menstrual 
cycle length. Physical examination, including 
weight, height, BMI (Kg/m2), hirsutism scoring 
(modified Ferriman Galway scoring), was 
recorded. Patients were advised to keep a record 
of menstrual cycles and weight.
Baseline investigations included CBC, Blood 
sugar fasting, fasting serum insulin. The 
hormonal analysis included serum FSH, LH, 
TSH, Prolactin, Testosterone, SHBG, and AMH 
done on days 2-3 of the previous menstrual 
cycles.
All patients were on the same drug according to 
the group allocated and, in addition, were given 
ovulation induction. For ovulation induction, 
tablet Letrozole 2.5 mg was started from day 3 to 
day 7 of the cycle. Transvaginal ultrasound (TVS) 
was done from day 9 of the cycle, and patients 
were followed with serial TVS till a mature follicle 
(>18 mm) was documented. Inj HCG 5000 IU was 
given when the mature follicle was documented. 
Patients were advised to maintain intercourse 
about 24 h following ovulation trigger to the next 
two more days. UPT   was done after overdue 
menses. Those with a negative urine pregnancy 
test and inadequate response were recruited for 
the second cycle of OVI with Letrozole 5 mg in 
addition to gonadotropins if the patient did not 
ovulate in the first cycle till the maximum of six 
cycles. After every subsequent cycle, patients 
who conceived were excluded from subsequent 
analysis. A record of dropouts was maintained.
The primary outcome measure was the 
clinical pregnancy rate. Secondary outcomes 
included improvement in clinical and hormonal 
parameters after drug therapy. Data statistical 
analysis was done. A p-value <0.05 was 
considered statistically significant.
results
A total of   96   patients with infertile PCOS were 
screened for this study. According to inclusion 
and exclusion criteria, 60 infertile PCOS women 
were selected for the study and were randomly 
assigned in two groups. Group A (n=30) was 
given Myoinositol 600 mg + Metformin 500 mg 
thrice a day, and Group B ( n=30) was given 
only Myoinositol 600 mg thrice a day. As shown 
in table 1, the baseline characteristics of the 
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patients were comparable in both groups.
Table 1: Baseline demographic and clinical 
characteristics between two groups
Characteristics Group A Group B p-Value
Age (years) 26.8±8.3 26.2±7.14 >0.05
BMI (kg/m2) 26.2±12.4 25.9±11.3 >0.05
Duration of 
infertility (Yrs)
3.2±0.8 3.8± 0.8 >0.05
Menstrual cycle 
length (Days)




9.3±2.5 10.3± 1.9 >0.05
P> 0.05 is statistically not significant. 
After six months, the length of the menstrual 
cycle was found to have improved significantly 
in Group A in comparison to Group B (p < 0.01). 
Table 2: Improvements in clinical parameters
Parameters Group A Group B Group A     Group B
At start After 6 
Months









9.3± 2.5 8.2± 1.7 10.3± 1.8 9.2± 2
Table 3: Improvement in hormonal parameters      
Parameters Group A  Group B Group A     Group B
At start After 6 
Months
At start After 6 
Months




7.2 ± 2.6 4.48± 1.7 7.9± 2.4 4.6± 2
p-value <0.01 <0.01








12.6± 7.4 22.2± 6.2 13.1± 6.2 23.1± 5.9
p-value <0.01 <0.01


















11± 3.7 9.5± 6.2
p-value <0.01 <0.01
Improvement in fasting blood sugar and insulin 
levels was statistically insignificant. The clinical 
parameters, BMI (p<0.01), modified Ferriman 
Gallaway score (p>0.05), and the was a significant 
improvement in the hormonal parameters in 
both the groups and the levels were found to be 
comparable after a period of 6 months (Table 2).
TABLE 4: Per cycle analysis of ovulation induction 
cycles between two groups.
Prameter Group Group A  P-









Conception 0 13 0 8 <0.01 *
Primary 0 11 0 7 <0.01 *
Secondary 0 2 0 1 >0.05 
*Signgicant 
The clinical pregnancy rate after six cycles of 
ovulation was significantly higher in Group 
A as compared to Group B. In Group A, the 
total clinical pregnancy rate was 43.33%, and 
in Group B, it was 26.67%, respectively, and 
the end of 6 months and the difference was 
statistically significant (p = <0.01) Table 4. 
dIscussIon
TThe present study shows a significantly 
higher live birth rate in women who receive the 
combination of metformin and Myo-inositol as 
compared to myo-inositol alone. Both metformin 
and Myo-inositol are insulin sensitizers. The 
mechanism of action of the two is different. 
PCOS is one of the most common endocrine 
disorders that affect women in their 
reproductive period [10]. Its characteristics are 
hyperandrogenism, anovulation for a prolonged 
period, and menstrual cycle irregularities [11].
Insulin receptor phosphorylation is found to be 
defective in about half of the patients with PCOS. 
12 Multiple trials have shown that insulin-
sensitizing agents, like metformin and MI, are 
the first-line treatment to normalize menstrual 
cycles in women who have PCOS [13]. Out of the 
patients suffering from amenorrhoea, most cases 
had spontaneous onset of menstruation. Most 
of the patients observed spontaneous menses 
within two months of treatment [14]. There 
was a statistically significant improvement in 
pregnancy rates after 24 weeks of treatment in 
patients treated with metformin and myoinositol 
[15].
In a study conducted by Chirania et al. in twenty-
two PCOS patients with menstrual irregularities 
achieved regular menses on their own, and 
most patients with infertility issues conceived. 
A vast reduction was also found in body weight, 
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fasting insulin, and acne. None of the patients 
required discontinuation of the drug due to any 
intolerable side effects [16].
In a study conducted by Thakur S et al., they 
found a significant improvement in parameters 
like irregular menstruation, skin changes, rate of 
conception, LH/FSH ratio, sensitivity to insulin, 
and HOMA-IR after six months of treatment 
in each of the three groups. However, it was 
observed that there was a better improvement 
in cases that were given a combination of 
metformin and myoinositol than myoinositol 
and metformin individually [15].
Metformin and myoinositol are both insulin 
sensitizers with different mechanisms of action 
[8].  Various studies confirm that myoinositol is 
an effective alternative in treating PCOS patients 
and a safe and secure drug as no side effects 
could be observed in the standard dosages. 
On the other side easy compliance results in a 
better outcome in the management of ovulation, 
hyperandrogenism, and metabolic parameters 
in patients with PCOS [17]. Our study shows 
a significantly higher live birth rate in women 
who received the combination of metformin and 
myoinositol as compared to metformin alone. 
Improved menstrual cyclicity was noted in 
both groups but was higher in the combination 
group. Improved ovulation may be the reason for 
spontaneous menses and a higher pregnancy 
rate in the combination group.
conclusIon 
The combined action of myoinositol and 
metformin has resulted in a significant reduction 
in the dose of the drug to be given but without 
affecting the drug’s efficacy. We observed equal 
response in reduction of hormonal levels and 
clinical and laboratory parameters in both the 
groups, while better results in terms of clinical 
fertility rates were observed in Group A – 
myoinositol with metformin. Further research in 
this regard is needed for better evaluation. We 
recommend a multi-centric study with a longer 
follow-up duration.
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